Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers

Gynecologic Oncology

Volumn 120, Issue 1, 2011, Pages 5-10

  Han, Jasmine J ^a   Yu, Minshu ^a   Houston, Nicole ^a   Steinberg, Seth M ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Epithelial ovarian cancer; Overall survival; Progranulin (PGRN); Progression free survival

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; PROGRANULIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HUMAN; KAPLAN MEIER METHOD; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; UPREGULATION; UTERINE CERVIX CARCINOMA IN SITU; VALIDATION PROCESS;

ADULT; AGED; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; TUMOR MARKERS, BIOLOGICAL;

EID: 78649904881     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.09.006     Document Type: Article

References (38)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. M.J. Horner, L.A.G. Ries, M. Krapcho, N. Neyman, R. Aminou, and N. Howlader SEER Cancer Statistics Review, 1975-2006 2009 National Cancer Institute Bethesda
3. G.L. Anderson, M. McIntosh, L. Wu, M. Barnett, G. Goodman, and J.D. Thorpe Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study J Natl Cancer Inst 102 2010 26 38
4. A.P. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, and W.T. Creasman Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer Int J Gynaecol Obstet 95 Suppl 1 2006 S161 S192
5. M.K. Tummala, and W.P. McGuire Recurrent ovarian cancer Clin Adv Hematol Oncol 3 2005 723 736
6. J.M. Riedinger, F. Bonnetain, J.P. Basuyau, N. Eche, H. Larbre, and I. Dalifard Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome Ann Oncol 18 2007 881 885
7. J.M. Riedinger, J. Wafflart, G. Ricolleau, N. Eche, H. Larbre, and J.P. Basuyau CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study Ann Oncol 17 2006 1234 1238
8. P. Sabbatini, and D.R. Spriggs Consolidation for ovarian cancer in remission J Clin Oncol 24 2006 537 539
9. R.C. Bast Jr., T.L. Klug, E. St John, E. Jenison, J.M. Niloff, and H. Lazarus A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 309 1983 883 887
10. I. Hellstrom, J. Raycraft, M. Hayden-Ledbetter, J.A. Ledbetter, M. Schummer, and M. McIntosh The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Res 63 2003 3695 3700
11. R. Drapkin, H.H. von Horsten, Y. Lin, S.C. Mok, C.P. Crum, and W.R. Welch Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas Cancer Res 65 2005 2162 2169
12. M.M. Tanner, S. Grenman, A. Koul, O. Johannsson, P. Meltzer, and T. Pejovic Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer Clin Cancer Res 6 2000 1833 1839
13. N. Devoogdt, N. Rasool, E. Hoskins, F. Simpkins, N. Tchabo, and E.C. Kohn Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo Cancer Sci 100 2009 434 440
14. N. Rasool, W. LaRochelle, H. Zhong, G. Ara, J. Cohen, and E.C. Kohn Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells Clin Cancer Res 16 2010 600 609
15. F.A. Simpkins, N.M. Devoogdt, N. Rasool, N.E. Tchabo, E.U. Alejandro, and M.M. Kamrava The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells Carcinogenesis 29 2008 466 472
16. Z. He, and A. Bateman Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis J Mol Med 81 2003 600 612
17. Z. He, A. Ismail, L. Kriazhev, G. Sadvakassova, and A. Bateman Progranulin (PC-cell-derived growth factor/acrogranin) regulates invasion and cell survival Cancer Res 62 2002 5590 5596
18. Z. He, C.H. Ong, J. Halper, and A. Bateman Progranulin is a mediator of the wound response Nat Med 9 2003 225 229
19. M.B. Jones, C.M. Michener, J.O. Blanchette, V.A. Kuznetsov, M. Raffeld, and G. Serrero The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer Clin Cancer Res 9 2003 44 51
20. M.B. Jones, M. Spooner, and E.C. Kohn The granulin-epithelin precursor: a putative new growth factor for ovarian cancer Gynecol Oncol 88 2003 S136 S139
21. M. Kamrava, F. Simpkins, E. Alejandro, C. Michener, E. Meltzer, and E.C. Kohn Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer Oncogene 24 2005 7084 7093
22. N. Matsumura, M. Mandai, M. Miyanishi, K. Fukuhara, T. Baba, and T. Higuchi Oncogenic property of acrogranin in human uterine leiomyosarcoma: direct evidence of genetic contribution in in vivo tumorigenesis Clin Cancer Res 12 2006 1402 1411
23. M. Miyanishi, M. Mandai, N. Matsumura, K. Yamaguchi, J. Hamanishi, and T. Higuchi Immortalized ovarian surface epithelial cells acquire tumorigenicity by Acrogranin gene overexpression Oncol Rep 17 2007 329 333
24. R.G. Moore, S. MacLaughlan, and R.C. Bast Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer Gynecol Oncol 116 2010 240 245
25. B. Davidson, E. Alejandro, V.A. Florenes, J.M. Goderstad, B. Risberg, and G.B. Kristensen Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma Cancer 100 2004 2139 2147
26. G.O. Pizarro, X.C. Zhou, A. Koch, M. Gharib, S. Raval, and K. Bible Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse Int J Cancer 120 2007 2339 2343
27. J. Zhu, C. Nathan, W. Jin, D. Sim, G.S. Ashcroft, and S.M. Wahl Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair Cell 111 2002 867 878
28. N. Devoogdt, G. Hassanzadeh Ghassabeh, J. Zhang, L. Brys, P. De Baetselier, and H. Revets Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells Proc Natl Acad Sci U S A 100 2003 5778 5782
29. N. Devoogdt, H. Revets, G.H. Ghassabeh, and P. De Baetselier Secretory leukocyte protease inhibitor in cancer development Ann NY Acad Sci 1028 2004 380 389
30. C.D. Hough, K.R. Cho, A.B. Zonderman, D.R. Schwartz, and P.J. Morin Coordinately up-regulated genes in ovarian cancer Cancer Res 61 2001 3869 3876
31. K. Shigemasa, H. Tanimoto, L.J. Underwood, T.H. Parmley, K. Arihiro, and K. Ohama Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors Int J Gynecol Cancer 11 2001 454 461
32. S. Tsukishiro, N. Suzumori, H. Nishikawa, A. Arakawa, and K. Suzumori Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis Gynecol Oncol 96 2005 516 519
33. D.S. Chi, K. McCaughty, J.P. Diaz, J. Huh, S. Schwabenbauer, and A.J. Hummer Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma Cancer 106 2006 1933 1939
34. Y.J. Na, J. Farley, A. Zeh, M. del Carmen, R. Penson, and M.J. Birrer Ovarian cancer: markers of response Int J Gynecol Cancer 19 Suppl 2 2009 S21 S29
35. A. Prat, M. Parera, B. Adamo, S. Peralta, M.A. Perez-Benavente, and A. Garcia Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels Ann Oncol 20 2009 294 297
36. G.J. Rustin, and M.E. van der Burg A randomized trial in ovarian cancer of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) J Clin Oncol 27 2009 18S
37. R. Cuevas-Antonio, C. Cancino, F. Arechavaleta-Velasco, A. Andrade, L. Barron, and I. Estrada Expression of progranulin (Acrogranin/PCDGF/Granulin- Epithelin Precursor) in benign and malignant ovarian tumors and activation of MAPK signaling in ovarian cancer cell line Cancer Invest 28 2009 452 458 (epub)
38. A. Prat, M. Parera, S. Peralta, M.A. Perez-Benavente, A. Garcia, and A. Gil-Moreno Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer Ann Oncol 19 2008 327 331